{"data":[{"accessionNo":"0001172661-26-003621","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001438533","issuerName":"TRAVERE THERAPEUTICS, INC.","ticker":"TVTX","cusip":"89422G107","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-06-30","reportingPerson":"Armistice Capital, LLC","reportingCik":null,"personType":"IA,OO","sharesOwned":1572539,"percentOfClass":1.67,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/tvtx"},{"accessionNo":"0001172661-26-003621","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001438533","issuerName":"TRAVERE THERAPEUTICS, INC.","ticker":"TVTX","cusip":"89422G107","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-06-30","reportingPerson":"Steven Boyd","reportingCik":null,"personType":"HC,IN","sharesOwned":1572539,"percentOfClass":1.67,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/tvtx"},{"accessionNo":"0000070858-26-000437","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001438533","issuerName":"Travere Therapeutics, Inc.","ticker":"TVTX","cusip":"89422G107","securityClass":"Common Stock","eventDate":"2026-06-30","reportingPerson":"BANK OF AMERICA CORP /DE/","reportingCik":null,"personType":"HC","sharesOwned":5439155,"percentOfClass":5.8,"filedAt":"2026-08-12","canonicalUrl":"https://xoomar.com/markets/stocks/tvtx"},{"accessionNo":"0000093751-26-000546","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001438533","issuerName":"TRAVERE THERAPEUTICS INC","ticker":"TVTX","cusip":"89422G107","securityClass":"COMMON STOCK","eventDate":"2026-06-30","reportingPerson":"STATE STREET CORPORATION","reportingCik":null,"personType":"HC","sharesOwned":4256224,"percentOfClass":4.6,"filedAt":"2026-08-07","canonicalUrl":"https://xoomar.com/markets/stocks/tvtx"},{"accessionNo":"0000315066-26-002183","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001438533","issuerName":"TRAVERE THERAPEUTICS INC","ticker":"TVTX","cusip":"89422G107","securityClass":"COMMON STOCK","eventDate":"2026-06-30","reportingPerson":"FMR LLC","reportingCik":null,"personType":"HC","sharesOwned":7142482.22,"percentOfClass":7.7,"filedAt":"2026-08-06","canonicalUrl":"https://xoomar.com/markets/stocks/tvtx"},{"accessionNo":"0000315066-26-002183","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001438533","issuerName":"TRAVERE THERAPEUTICS INC","ticker":"TVTX","cusip":"89422G107","securityClass":"COMMON STOCK","eventDate":"2026-06-30","reportingPerson":"Abigail P. Johnson","reportingCik":null,"personType":"IN","sharesOwned":7142482.22,"percentOfClass":7.7,"filedAt":"2026-08-06","canonicalUrl":"https://xoomar.com/markets/stocks/tvtx"},{"accessionNo":"0001172661-26-002146","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001438533","issuerName":"TRAVERE THERAPEUTICS, INC.","ticker":"TVTX","cusip":"89422G107","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-03-31","reportingPerson":"Armistice Capital, LLC","reportingCik":null,"personType":"IA,OO","sharesOwned":4897417,"percentOfClass":5.27,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/tvtx"},{"accessionNo":"0001172661-26-002146","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001438533","issuerName":"TRAVERE THERAPEUTICS, INC.","ticker":"TVTX","cusip":"89422G107","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-03-31","reportingPerson":"Steven Boyd","reportingCik":null,"personType":"HC,IN","sharesOwned":4897417,"percentOfClass":5.27,"filedAt":"2026-05-15","canonicalUrl":"https://xoomar.com/markets/stocks/tvtx"},{"accessionNo":"0002100119-26-001151","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001438533","issuerName":"Travere Therapeutics Inc","ticker":"TVTX","cusip":"89422G107","securityClass":"Common Stock","eventDate":"2026-03-31","reportingPerson":"Vanguard Capital Management","reportingCik":null,"personType":"IA","sharesOwned":4699424,"percentOfClass":5.09,"filedAt":"2026-04-30","canonicalUrl":"https://xoomar.com/markets/stocks/tvtx"},{"accessionNo":"0000102909-26-002431","formType":"SCHEDULE 13G/A","amendmentNo":9,"issuerCik":"0001438533","issuerName":"Travere Therapeutics Inc","ticker":"TVTX","cusip":"89422G107","securityClass":"Common Stock","eventDate":"2026-03-13","reportingPerson":"The Vanguard Group","reportingCik":null,"personType":"IA","sharesOwned":0,"percentOfClass":0,"filedAt":"2026-03-27","canonicalUrl":"https://xoomar.com/markets/stocks/tvtx"},{"accessionNo":"0001193125-26-054520","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001438533","issuerName":"TRAVERE THERAPEUTICS, INC.","ticker":"TVTX","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-12-31","reportingPerson":"Joseph Edelman","reportingCik":null,"personType":"IN","sharesOwned":4278180,"percentOfClass":4.8,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/tvtx"},{"accessionNo":"0001193125-26-054520","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001438533","issuerName":"TRAVERE THERAPEUTICS, INC.","ticker":"TVTX","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-12-31","reportingPerson":"Perceptive Advisors LLC","reportingCik":null,"personType":"IA","sharesOwned":4278180,"percentOfClass":4.8,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/tvtx"},{"accessionNo":"0001193125-26-054520","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001438533","issuerName":"TRAVERE THERAPEUTICS, INC.","ticker":"TVTX","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-12-31","reportingPerson":"Perceptive Life Sciences Master Fund, Ltd.","reportingCik":null,"personType":"CO","sharesOwned":4278180,"percentOfClass":4.8,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/tvtx"},{"accessionNo":"0001172661-26-001227","formType":"SCHEDULE 13G/A","amendmentNo":8,"issuerCik":"0001438533","issuerName":"TRAVERE THERAPEUTICS, INC.","ticker":"TVTX","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-12-31","reportingPerson":"Steven Boyd","reportingCik":null,"personType":"HC,IN","sharesOwned":3763891,"percentOfClass":4.21,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/tvtx"},{"accessionNo":"0001172661-26-001227","formType":"SCHEDULE 13G/A","amendmentNo":8,"issuerCik":"0001438533","issuerName":"TRAVERE THERAPEUTICS, INC.","ticker":"TVTX","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-12-31","reportingPerson":"Armistice Capital, LLC","reportingCik":null,"personType":"IA,OO","sharesOwned":3763891,"percentOfClass":4.21,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/tvtx"},{"accessionNo":"0001193125-26-049707","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001438533","issuerName":"Travere Therapeutics Inc","ticker":"TVTX","cusip":null,"securityClass":"Common Shares","eventDate":"2025-12-31","reportingPerson":"Macquarie Group Limited","reportingCik":null,"personType":"HC","sharesOwned":0,"percentOfClass":0,"filedAt":"2026-02-13","canonicalUrl":"https://xoomar.com/markets/stocks/tvtx"},{"accessionNo":"0001193125-26-049707","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001438533","issuerName":"Travere Therapeutics Inc","ticker":"TVTX","cusip":null,"securityClass":"Common Shares","eventDate":"2025-12-31","reportingPerson":"Macquarie Management Holdings Inc","reportingCik":null,"personType":"HC","sharesOwned":0,"percentOfClass":0,"filedAt":"2026-02-13","canonicalUrl":"https://xoomar.com/markets/stocks/tvtx"},{"accessionNo":"0001193125-26-049707","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001438533","issuerName":"Travere Therapeutics Inc","ticker":"TVTX","cusip":null,"securityClass":"Common Shares","eventDate":"2025-12-31","reportingPerson":"Macquarie Investment Management Business Trust","reportingCik":null,"personType":"IA","sharesOwned":0,"percentOfClass":0,"filedAt":"2026-02-13","canonicalUrl":"https://xoomar.com/markets/stocks/tvtx"},{"accessionNo":"0000093751-26-000092","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001438533","issuerName":"TRAVERE THERAPEUTICS INC","ticker":"TVTX","cusip":null,"securityClass":"COMMON STOCK","eventDate":"2025-12-31","reportingPerson":"STATE STREET CORPORATION","reportingCik":null,"personType":"HC","sharesOwned":4756666,"percentOfClass":5.3,"filedAt":"2026-02-09","canonicalUrl":"https://xoomar.com/markets/stocks/tvtx"},{"accessionNo":"0000315066-26-000051","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001438533","issuerName":"TRAVERE THERAPEUTICS INC","ticker":"TVTX","cusip":null,"securityClass":"COMMON STOCK","eventDate":"2025-12-31","reportingPerson":"Abigail P. Johnson","reportingCik":null,"personType":"IN","sharesOwned":10567302.78,"percentOfClass":11.7,"filedAt":"2026-01-08","canonicalUrl":"https://xoomar.com/markets/stocks/tvtx"},{"accessionNo":"0000315066-26-000051","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001438533","issuerName":"TRAVERE THERAPEUTICS INC","ticker":"TVTX","cusip":null,"securityClass":"COMMON STOCK","eventDate":"2025-12-31","reportingPerson":"FMR LLC","reportingCik":null,"personType":"HC","sharesOwned":10567302.78,"percentOfClass":11.7,"filedAt":"2026-01-08","canonicalUrl":"https://xoomar.com/markets/stocks/tvtx"},{"accessionNo":"0001274173-25-000318","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001438533","issuerName":"TRAVERE THERAPEUTICS, INC","ticker":"TVTX","cusip":null,"securityClass":"Common Stock","eventDate":"2025-09-30","reportingPerson":"JANUS HENDERSON GROUP PLC","reportingCik":null,"personType":"IA,HC","sharesOwned":10599660,"percentOfClass":11.9,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/tvtx"},{"accessionNo":"0001172661-25-005160","formType":"SCHEDULE 13G/A","amendmentNo":7,"issuerCik":"0001438533","issuerName":"TRAVERE THERAPEUTICS, INC.","ticker":"TVTX","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-09-30","reportingPerson":"Armistice Capital, LLC","reportingCik":null,"personType":"IA,OO","sharesOwned":6724000,"percentOfClass":7.52,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/tvtx"},{"accessionNo":"0001172661-25-005160","formType":"SCHEDULE 13G/A","amendmentNo":7,"issuerCik":"0001438533","issuerName":"TRAVERE THERAPEUTICS, INC.","ticker":"TVTX","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-09-30","reportingPerson":"Steven Boyd","reportingCik":null,"personType":"HC,IN","sharesOwned":6724000,"percentOfClass":7.52,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/tvtx"},{"accessionNo":"0001193125-25-238357","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001438533","issuerName":"TRAVERE THERAPEUTICS, INC.","ticker":"TVTX","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-10-06","reportingPerson":"Perceptive Advisors LLC","reportingCik":null,"personType":"IA","sharesOwned":4895615,"percentOfClass":5.5,"filedAt":"2025-10-14","canonicalUrl":"https://xoomar.com/markets/stocks/tvtx"},{"accessionNo":"0001193125-25-238357","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001438533","issuerName":"TRAVERE THERAPEUTICS, INC.","ticker":"TVTX","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-10-06","reportingPerson":"Perceptive Life Sciences Master Fund, Ltd.","reportingCik":null,"personType":"CO","sharesOwned":4895615,"percentOfClass":5.5,"filedAt":"2025-10-14","canonicalUrl":"https://xoomar.com/markets/stocks/tvtx"},{"accessionNo":"0001193125-25-238357","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001438533","issuerName":"TRAVERE THERAPEUTICS, INC.","ticker":"TVTX","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-10-06","reportingPerson":"Joseph Edelman","reportingCik":null,"personType":"IN","sharesOwned":4895615,"percentOfClass":5.5,"filedAt":"2025-10-14","canonicalUrl":"https://xoomar.com/markets/stocks/tvtx"}],"updatedAt":"2026-11-04T01:11:25.288Z","source":"xoomar.com","docs":"https://xoomar.com/markets/api","license":"https://xoomar.com/terms","attribution":"Credit XOOMAR with a link to the dataset page on xoomar.com when you republish this data","canonicalUrl":"https://xoomar.com/markets/stocks/tvtx","meta":{"source":"SEC","sourceAttribution":"Schedule 13D and 13G data: SEC.","notice":"10 requests a minute without a key, 30 with a free key. Get a free key at https://xoomar.com/signup?utm_source=api, register your app at https://xoomar.com/developers/register?utm_source=api, and credit the data as \"Data: XOOMAR\" together with the sourceAttribution line."}}